A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD.

NCT07116915 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: HRS-9821 Powder for Inhalation/HRS-9821 inhalation suspension
DRUG: HRS-9821 Powder for Inhalation placebo/HRS-9821 inhalation suspension placebo
DRUG: Moxifloxacin Hydrochloride Tablets

Sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd